Telix Shares Surge Following Surprise Deal with Regeneron
Telix Pharmaceuticals (ASX:TLX) has seen a significant rise in its share price, with shares climbing as much as 8.8% following a surprise deal with Regeneron. The collaboration is focused on the development of nuclear medicine cancer therapies for “multiple solid tumour targets” within the biologics sector.
The partnership involves Indianapolis-based Regeneron, a Nasdaq-listed company with a market capitalization of US$80 billion. Regeneron specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. This collaboration brings together Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s capabilities in antibody discovery and oncology experience.
Biologics are complex medications derived from living organisms such as cells or tissues, rather than synthetic chemicals. The envisaged clinical programs will complement Telix’s current efforts, which primarily focus on imaging and therapies for prostate, kidney, and brain cancer.
Financial Details of the Deal
Initially, Telix will receive a US$40 million upfront payment for four initial programs. The company has the option to co-fund commercialisation and development and share profits, potentially earning up to a total of US$2.1 billion in development and commercial milestones. Additionally, Telix would be entitled to low double-digit royalties.
Alternatively, if Telix chooses not to co-fund a particular program, it could receive up to US$535 million in development and commercial milestones, along with royalties. Regeneron also has the option to expand the collaboration to four additional programs, with further upfront payments for Telix.
Both companies will jointly develop diagnostic assets, with Telix leading commercialisation and Regeneron receiving a set percentage of profits.
Dr Chris Behrenbruch, CEO of Telix, highlighted the significance of the collaboration, stating, “The collaboration reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients.”
Although the announcement does not specify the cancer indications the companies will pursue, a Regeneron senior vice president, Dr Israel Lowy, mentioned the company’s interest in targeted radiopharmaceuticals that could be used as monotherapies or in combination with Regeneron’s immunotherapy platform. The focus areas include lung cancer, an area with high unmet patient needs.
Monash IVF Group Considers Improved Takeover Proposal
Monash IVF Group (ASX:MVF) is currently assessing an improved indicative takeover proposal from a consortium consisting of Genesis Capital Investment Management and Washington H Soul Pattinson (ASX:SOL). The new offer is 90 cents per share in cash via a scheme of arrangement, compared to the previous 80 cents.
This fresh proposal values the company at $350 million. The board is evaluating the offer, including seeking advice from its financial and legal advisers. The bidders have stated that their price is the highest they are willing to offer, “absent a competing proposal.” The offer is valid until close of business on the following Tuesday.
The bid depends on several factors, including Monash IVF’s board endorsement. Given that the consortium holds 19.6% of the Monash IVF register, no other party can move forward without its approval.
Monash IVF shares experienced a significant increase, rising as much as 19% to 80 cents. The stock reached a seven-year high of $1.50 in March 2024.
Arovella Therapeutics Faces Board Tilt
A trio of well-known biotech names is behind a board tilt at cancer cell therapy developer Arovella Therapeutics (ASX:ALA). The Trust Company (Australia) Limited intends to force a shareholder meeting to elect David Williams, Mark Diamond, and Michael Thurn as directors.
As a shareholder holding more than 5%, The Trust Company can initiate this under section 249D of the Corporations Act. The proposed directors bring extensive experience in the biotech sector, with backgrounds in various companies.
Arovella is currently deciding the validity of the “purported” notice. If deemed valid, the company must call a meeting within 21 days and hold it within two months. The board notes that the resolution does not include a proposal to remove any existing Arovella directors.
Pro Medicus Secures Major Contract Renewals
Pro Medicus (ASX:PME) has renewed a five-year, $37 million contract with the Chicago-based hospital system, Northwestern Medicine. The deal includes increased minimum payments and higher fees per transaction.
Diligent readers may recall that the company recently unveiled a five-year $23 million contract with the University of Maryland Medical System. CEO and co-founder Dr Sam Hupert emphasized the importance of client retention, stating, “In the last month we have contracted nearly $80 million in renewals, maintaining our track record when it comes to client retention.”
This underpins the company’s belief that its solution provides unparalleled return on investment from both a financial and clinical perspective. Pro Medicus shares have gained 7% over the last week despite recent challenges.
